{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is NanoViricides, Inc. technically bullish or bearish?
As of June 18, 2025, the trend is mildly bullish with supportive signals from the MACD and daily moving averages, but caution is advised due to bearish Bollinger Bands and mixed momentum indicators.
Who are in the management team of NanoViricides, Inc.?
As of March 2022, the management team of NanoViricides, Inc. includes Dr. Anil Diwan as Executive Chairman and President, along with independent directors Mr. Stanley Glick, Mr. Makarand Jawadekar, Mr. Theodore Rokita, and Mr. Brian Zucker.
What does NanoViricides, Inc. do?
NanoViricides, Inc. is a nano-biopharmaceutical company focused on developing drugs for viral infections, with a market cap of $21.54 million and a recent net profit of -$2 million. The company operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap firm.
How big is NanoViricides, Inc.?
As of Jun 24, NanoViricides, Inc. has a market capitalization of 21.54 million, with net sales of 0.00 million and a net profit of -9.74 million over the latest four quarters. Shareholder's funds are 11.46 million and total assets are 12.82 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
